MAXCYTE INC. - COMMON STOCK

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

13 Jan 2025 03:05:00 By Nasdaq GlobeNewswire

MaxCyte Announces Retirement of Board Member Art Mandell

23 Dec 2024 02:00:00 By Nasdaq GlobeNewswire

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

09 Dec 2024 02:00:00 By Nasdaq GlobeNewswire

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

13 Nov 2024 08:05:00 By Nasdaq GlobeNewswire

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

06 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

MaxCyte to Participate in Two Upcoming Investor Conferences

31 Oct 2024 08:05:00 By Nasdaq GlobeNewswire

MaxCyte Appoints Cynthia Collins to its Board of Directors

15 Oct 2024 08:05:00 By Nasdaq GlobeNewswire

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

11 Oct 2024 08:05:00 By Nasdaq GlobeNewswire

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

10 Oct 2024 08:05:00 By Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

16 Sep 2024 02:00:00 By Nasdaq GlobeNewswire

MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference

05 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance

06 Aug 2024 16:05:01 By Nasdaq GlobeNewswire

MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024

09 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference

29 May 2024 08:05:00 By Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development

22 May 2024 08:05:00 By Nasdaq GlobeNewswire

MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance

07 May 2024 16:05:01 By Nasdaq GlobeNewswire

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

10 Apr 2024 08:05:00 By Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

02 Apr 2024 08:05:00 By Nasdaq GlobeNewswire

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

12 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

04 Mar 2024 16:05:00 By Nasdaq GlobeNewswire